CVS Health , which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' new HIV prevention drug to ...

The Gilead HIV prevention shot , called Yevtugo, is highly effective, but its list price is $28, 218 a year in the U.S.

Gilead Sciences (($GILD)) announced an update on their ongoing clinical study. Gilead Sciences is currently recruiting participants for a clinical ...

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

Gilead Sciences (($CC:GILD.CUR)) announced an update on their ongoing clinical study. Gilead Sciences is conducting a ...

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) fell 3.5% in the morning session after reports that CVS ...

Gilead shares slip after CVS refused to add its new HIV drug, Yeztugo, while its Kite unit struck a $350 million deal with ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

Gilead Sciences is a fantastic company that's revolutionized the treatment of numerous diseases. But click here to read why ...

Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to its commercial ...